Antibodies and Antibody Drug Conjugates 2018 is a conference that covers topics such as:
- New and novel payloads, e.g. Antibody Targeted Amanitin Conjugates (ATACs) and minorgroove binding DNA-interactive molecules as ADC payloads, to expand the ADC landscape
- The implementation of superior technologies to develop more effective and efficient Antibody Drug Conjugates
- Using fragment conjugates in order to develop a tailored therapy for solid tumours
- The practicalities of the use of Highly Potent Active Pharmaceutical Ingredients
- Maximising the drug delivery efficiency and therapeutic index
Antibodies and Antibody Drug Conjugates 2018 brings together:
- Senior Scientists
- Research & Development Directors/Managers/Scientists
- Chief Medical Officers
- Chief Scientific Officers
- Heads of Pre-Clinical Development
- Heads of Clinical Development
- Global Presence: